Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) has been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $17.1333.
Several research analysts recently commented on the stock. Wells Fargo & Company reduced their price target on shares of Alphatec from $28.00 to $14.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. HC Wainwright reissued a “buy” rating and issued a $24.00 price objective on shares of Alphatec in a research report on Thursday, May 7th. JPMorgan Chase & Co. dropped their target price on shares of Alphatec from $24.00 to $16.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings raised shares of Alphatec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 6th. Finally, UBS Group started coverage on shares of Alphatec in a research report on Tuesday, July 28th. They set a “buy” rating and a $15.00 target price on the stock.
Read Our Latest Analysis on ATEC
Insider Transactions at Alphatec
Hedge Funds Weigh In On Alphatec
Institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Alphatec by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company’s stock valued at $750,000 after acquiring an additional 3,196 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Alphatec in the first quarter worth about $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Alphatec by 18.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company’s stock worth $2,696,000 after acquiring an additional 41,264 shares in the last quarter. Quantbot Technologies LP bought a new position in Alphatec during the 2nd quarter worth about $242,000. Finally, Invesco Ltd. increased its position in Alphatec by 455.0% during the 2nd quarter. Invesco Ltd. now owns 282,212 shares of the medical technology company’s stock valued at $3,133,000 after purchasing an additional 231,367 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.
Alphatec Stock Performance
ATEC stock opened at $9.52 on Monday. Alphatec has a twelve month low of $6.82 and a twelve month high of $23.29. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -11.61 and a beta of 0.85. The business’s fifty day simple moving average is $8.62 and its two-hundred day simple moving average is $10.91. The company has a quick ratio of 1.12, a current ratio of 1.90 and a debt-to-equity ratio of 40.35.
Alphatec Company Profile
Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.
Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.
Featured Stories
- Five stocks we like better than Alphatec
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.
